𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Ten years of cholinesterase inhibitors

✍ Scribed by Joanne Rodda; Zuzana Walker

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
141 KB
Volume
24
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

In this editorial we have summarised ten years of evidence relating to the use of cholinesterase inhibitors in Alzheimer's and other dementias. We have presented this evidence in the context of the evolution of public and professional awareness of dementia and its management and prescribing patterns over this time frame. We also briefly outline recent political and legal events surrounding the 2007 NICE guidance and the possible long‐term impact of cholinesterase inhibitors on clinical practice. Whilst cholinesterase inhibitors continue to play a part in the management of Alzheimer's disease, it is possible that their most important legacy will be their contribution to the increased awareness and recognition of dementia as a neurodegenerative disease and the resulting transformation of old age psychiatry services. Copyright Β© 2009 John Wiley & Sons, Ltd.

πŸ“œ SIMILAR VOLUMES

Ten years of fluoxetine
Ten years of fluoxetine
✍ Peter E. Stokes πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 42 KB πŸ‘ 2 views
Clinical effects of organophosphorus cho
Clinical effects of organophosphorus cholinesterase inhibitors
✍ Frederick R. Sidell πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 355 KB

Nerve agents, highly toxic organophosphorus cholinesterase inhibitors, inhibit acetylcholinesterase and cause an accumulation of acetylcholine. Clinical effects depend on the route and amount of exposure and include miosis, bronchoconstriction, excessive secretions, vomiting, seizures, and cessation

Ten years of muscle & nerve
Ten years of muscle & nerve
✍ Walter G. Bradley πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 134 KB
Cholinesterase inhibitors in the treatme
Cholinesterase inhibitors in the treatment of dementia
✍ Maria Luisa Margallo-Lana; Clive Ballard; Chris Morris; David Kay; Stephen Tyrer πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 36 KB

fact may be ascribed to a primarily biological origin of the disease, not correlated with other possible causative events (e.g. chronic somatic diseases). On the other hand, in patients with reactive depressive symptoms a higher prevalence of somatic dysfunction (e.g. number of diseases, Charlson In